Michael R McKenna1, Derrick J Stobaugh1, Parakkal Deepak2. 1. Research Institute, NorthShore University HealthSystem, Evanston, IL, 60201, USA. 2. Department of Gastroenterology, Mayo Clinic, Rochester, MN, 55905, USA. deepak.parakkal@mayo.edu.
Abstract
BACKGROUND AND AIMS: Reports have shown an increased risk of melanoma skin cancer (MSC) with exposure to tumor necrosis factor alpha (TNF-α) inhibitors and non-melanoma skin cancer (NMSC) with thiopurine exposure in inflammatory bowel disease (IBD) patients. Using the Food and Drug Administration Adverse Event Reporting System (FAERS) we sought to evaluate the odds of developing MSC and NMSC for patients on TNF-α inhibitors as monotherapy and in combination therapy with thiopurines and/or steroids. METHODS: The FAERS was queried for reports between January 2003 and June 2012. A proportional reporting ratio (PRR) metric analyses was performed on the data to determine the odds of developing MSC and NMSC. RESULTS: The PRR analysis showed increased odds of developing MSC and NMSC for patients on a TNF-α inhibitor (p-value = 0.035 and p-value = 0.03, respectively) and those on a TNF-α inhibitor in combination with a thiopurine (p-value < 0.001 and p-value < 0.001). CONCLUSION: TNF-α inhibitor monotherapy or use with concomitant thiopurines in patients with IBD is associated with higher odds of developing MSC and NMSC.
BACKGROUND AND AIMS: Reports have shown an increased risk of melanoma skin cancer (MSC) with exposure to tumor necrosis factor alpha (TNF-α) inhibitors and non-melanoma skin cancer (NMSC) with thiopurine exposure in inflammatory bowel disease (IBD) patients. Using the Food and Drug Administration Adverse Event Reporting System (FAERS) we sought to evaluate the odds of developing MSC and NMSC for patients on TNF-α inhibitors as monotherapy and in combination therapy with thiopurines and/or steroids. METHODS: The FAERS was queried for reports between January 2003 and June 2012. A proportional reporting ratio (PRR) metric analyses was performed on the data to determine the odds of developing MSC and NMSC. RESULTS: The PRR analysis showed increased odds of developing MSC and NMSC for patients on a TNF-α inhibitor (p-value = 0.035 and p-value = 0.03, respectively) and those on a TNF-α inhibitor in combination with a thiopurine (p-value < 0.001 and p-value < 0.001). CONCLUSION: TNF-α inhibitor monotherapy or use with concomitant thiopurines in patients with IBD is associated with higher odds of developing MSC and NMSC.
Authors: María Chaparro; M Ramas; J M Benítez; A López-García; A Juan; J Guardiola; M Mínguez; X Calvet; L Márquez; L I Fernández Salazar; L Bujanda; C García; Y Zabana; R Lorente; J Barrio; E Hinojosa; M Iborra; M Domínguez Cajal; M Van Domselaar; M F García-Sepulcre; F Gomollón; M Piqueras; G Alcaín; V García-Sánchez; J Panés; E Domènech; E García-Esquinas; F Rodríguez-Artalejo; J P Gisbert Journal: Am J Gastroenterol Date: 2017-05-23 Impact factor: 10.864
Authors: Alyce Anderson; Laura K Ferris; Benjamin Click; Claudia Ramos-Rivers; Ioannis E Koutroubakis; Jana G Hashash; Michael Dunn; Arthur Barrie; Marc Schwartz; Miguel Regueiro; David G Binion Journal: Dig Dis Sci Date: 2018-04-30 Impact factor: 3.199